This Administrative Core will mediate three functions. As part of the first function it will help coordinate the Principal Project, the Collaborative Project and the Pilot Project. At a fixed time on the first Monday of every month the project coordinator and the Investigators and Co-investigators of the three projects will meet face-to-face or by conference call at Massachusetts General Hospital to chart progress and coordinate studies and sample collection. These meetings will expand on ongoing regular monthly meetings currently being held. A second goal of this Core will be to make available tools of Human Immunology research to other investigators at MGH studying autoimmune disorders other than lgG4-Related Disease including Next Gen sequencing for repertoire, expertise with the Cytof, cell storage and profiling techniques. The ACE program coordinator will regularly inform the broader MGH community of the time and location of the monthly meetings and an hour will be set aside by the Principal Investigator to meet clinicians and other investigators at the MGH who seek to interact. These interactions will also facilitate some of the studies of the Principal Project on an unusual type of disease causing human T cell subset. The third goal of this Core and its coordinator will be to generate a portal for interaction with other ACEs and to share information on Immune repertoires, microbial community characteristics and eventually Immunochip data with other groups working across the country on autoimmunity, not necessarily restricted to other ACEs
Coordinated Efforts will be required to better understand the underlying mechanisms causing human autoimmune diseases. This ACE involves investigators different departments at Massachusetts General Hospital and the Broad Institute of Harvard and MIT. Since many diseases utilize common mechanisms the exchange of information and ideas is crucial to progress.
|Mattoo, Hamid; Mahajan, Vinay S; Della-Torre, Emanuel et al. (2014) De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. J Allergy Clin Immunol 134:679-87|